Argenx Shares Rise After Positive Results from Phase 3 Study of Efgartigimod
Dow Jones
Aug 17
Shares in Argenx rose after the European pharmaceutical company reported positive results from the phase 3 trial of Efgartigimod for the treatment of autoimmune myositis.
In early morning trading, shares were up 8% at 788.40 euros. Year to date, shares have risen 10%.
The company said Monday that patients demonstrated greater improvement both statistically and clinically at week 52 versus placebo.
Efgartigimod was well-tolerated by patients during the study, the company added.
"The patient response to efgartigimod was durable and multidimensional: separation from placebo emerged early and held through a full year of treatment, with a treatment effect of comparable magnitude in immune-mediated necrotizing myopathy and dermatomyositis," Chief Medical Officer Luc Truyen said.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.